Search by Drug Name or NDC

    NDC 00002-7575-01 Omvoh 20 mg/mL Details

    Omvoh 20 mg/mL

    Omvoh is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is MIRIKIZUMAB.

    Product Information

    NDC 00002-7575
    Product ID 0002-7575_83c555b7-3807-4f0b-8812-63b6082d026c
    Associated GPIs
    GCN Sequence Number 085440
    GCN Sequence Number Description mirikizumab-mrkz VIAL 300MG/15ML INTRAVEN
    HIC3 V4E
    HIC3 Description IL-23 RECEPTOR ANTAGONIST, MONOCLONAL ANTIBODY
    GCN 54923
    HICL Sequence Number 049282
    HICL Sequence Number Description MIRIKIZUMAB-MRKZ
    Brand/Generic Brand
    Proprietary Name Omvoh
    Proprietary Name Suffix n/a
    Non-Proprietary Name mirikizumab-mrkz
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 20
    Active Ingredient Units mg/mL
    Substance Name MIRIKIZUMAB
    Labeler Name Eli Lilly and Company
    Pharmaceutical Class Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761279
    Listing Certified Through 2024-12-31

    Package

    NDC 00002-7575-01 (00002757501)

    NDC Package Code 0002-7575-01
    Billing NDC 00002757501
    Package 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-7575-01) / 15 mL in 1 VIAL, SINGLE-DOSE
    Marketing Start Date 2023-10-26
    NDC Exclude Flag N
    Pricing Information N/A